The HCM City Oncology Hospital on August 27 renews an MoU with AstraZeneca Vietnam Company Limited for improving the quality of care for cancer patients in 2024-27. — Photo Courtesy of AstraZeneca Vietnam 

The HCM City Oncology Hospital and AstraZeneca Vietnam Company Limited continue their cooperation to improve the quality of treatment for cancer patients.

They has renewed an existing memorandum of understanding for 2024-27.

They agreed to accelerate research and international integration of the hospital, improving the quality of treatment for cancer patients.

Their key areas of cooperation include promoting clinical research, training, innovation, building epidemiological information, and treatment.

Diep Bao Tuan, deputy director of the hospital, said the agreement  expands both the breadth and depth of cooperation.

“I believe we will achieve new breakthroughs in treatment, helping improve the effectiveness of cancer treatment."  

The two sides prioritise promoting the goal of equality in healthcare through the application of artificial intelligence in early screening for lung cancer.

They will cooperate to establish the first "Cancer Genetic Counseling Unit" in the country, Tuan added.

Atul Tandon, general director of AstraZeneca Vietnam, said this cooperation is completely in line with the company’s strategic vision and Viet Nam's broader health goals.

“We will create practical impacts on the lives of cancer patients and their families, contributing to a healthier and more prosperous Viet Nam.”

In the first phase from 2021 to 2023, the two sides carried out programmes for patients such as subsidising low-dose CT scan costs, propagating the screening and early detection of lung cancer, sponsoring late-stage EGFR testing for patients without health insurance, supporting pathologists trained abroad in diagnosing breast cancer, and doing research at the hospital.

They set up the "Chat Club with oncologists - patients - relatives" and received enthusiastic support from leading doctors about the treatment and management of the disease. — VNS